Co-administration of FGF-21 and GLP-1 to treat diabetes and lower blood glucose
AssigneeEli Lilly and Company
InventorsTamer Coskun, Wolfgang Glaesner
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of lowering body weight by administering an FGF-21 compound in combination with a GLP-1 compound. In addition, the present invention also provides methods to treat obesity by administering an FGF-21 compound in combination with a GLP-1 compound. The present invention also discloses combinations useful in the methods of the present invention.
Claims2
A method of treating diabetes comprising administering an FGF-21 compound in combination with a GLP-1 compound, wherein the FGF-21 compound has the amino acid sequence of SEQ ID NO:
- 2, and wherein the GLP-1 compound has the amino acid sequence of SEQ ID NO:
- 19.
A method of lowering blood glucose levels comprising administering an FGF-21 compound in combination with a GLP-1 compound, wherein the FGF-21 compound has the amino acid sequence of SEQ ID NO:
- 2, and wherein the GLP-1 compound has the amino acid sequence of SEQ ID NO:
- 19.
Dependencies are inferred from the claim text.